• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TICAGRELOR Drug Record

  • Summary
  • Interactions
  • Claims
  • TICAGRELOR chembl:CHEMBL398435 Approved

    Alternate Names:

    AR-C126532XX
    TICAGRELOR
    BRILINTA
    AZD-6140
    BRILIQUE
    BRILIQUE®
    AZD 6140
    AZD6140
    (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYLAMINO)-5-(PROPYLTHIO)-3H-(1,2,3)TRIAZOLO(4,5-D)PYRIMIDIN-3-YL)-5-(2-HYDROXYETHOXY)CYCLOPENTANE-1,2-DIOL
    BRILINTA®
    chemidplus:274693-27-5
    drugbank:08816
    rxcui:1116632
    pubchem.compound:9871419
    chembl:CHEMBL398435

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications antithrombotic
    (1 More Sources)

    Publications:

    Varenhorst C et al., 2015, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes., Eur Heart J
    Storey et al., 2007, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes., J. Am. Coll. Cardiol.
    Springthorpe et al., 2007, From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis., Bioorg. Med. Chem. Lett.
    Chan NC et al., 2014, Role of phenotypic and genetic testing in managing clopidogrel therapy., Blood
    Teng R, 2015, Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update., Clin Pharmacokinet
    Malhotra N et al., 2015, A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window., Int J Cardiol
    Li M et al., 2017, Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers., Xenobiotica
  • TICAGRELOR   PEAR1

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27937053


    Sources:
    PharmGKB

  • TICAGRELOR   P2RY12

    Interaction Score: 4.42

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Purinergic receptor P2Y12 negative allosteric modulator
    Novel drug target Established target

    PMIDs:
    17980251 17827008 24951432 26063049


    Sources:
    TdgClinicalTrial ChemblInteractions PharmGKB

  • TICAGRELOR   CYP3A43

    Interaction Score: 2.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25935875


    Sources:
    PharmGKB

  • TICAGRELOR   UGT2B7

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25935875


    Sources:
    PharmGKB

  • TICAGRELOR   SLCO1B1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25935875


    Sources:
    PharmGKB

  • TICAGRELOR   CYP2C19

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26151596


    Sources:
    PharmGKB FDA

  • TICAGRELOR   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25935875


    Sources:
    PharmGKB

  • TdgClinicalTrial: TICAGRELOR

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antithrombotic
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: ticagrelor

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Varenhorst C et al., 2015, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes., Eur Heart J
    Chan NC et al., 2014, Role of phenotypic and genetic testing in managing clopidogrel therapy., Blood
    Malhotra N et al., 2015, A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window., Int J Cardiol

  • ChemblDrugs: chembl:CHEMBL398435

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL398435

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ticagrelor

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21